Exemplos de uso de Total bilirubin em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Increased total bilirubin.
High creatine phosphokinase Increased total bilirubin.
Elevations in total bilirubin, mainly mild to moderate.
Other laboratory findings showed normal total bilirubin 0.9 mg/dL.
The total bilirubin should be≤ 1.5 times upper limit of normal.
Severe hepatic impairment total bilirubin> 3 x ULN.
Total bilirubin and liver enzymes were mildly elevated, and CBC was normal.
The increase correlated with total bilirubin concentrations.
Grade 2 elevation in aspartate aminotransferase(AST),alanine aminotransferase(ALT), or total bilirubin.
Jaundice was defined as serum total bilirubin greater than 5 mg/dl.
Levels of Transcutaneous Bilirubinometry TcB and Serum Total Bilirubin.
Grade 3 or 4 elevation of total bilirubin was noted in 37% 6% Grade 4.
There was no evidence of dependencies on age,creatinine clearance, total bilirubin, or disease.
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels16.
AST:> ULN can be normal or<ULN if total bilirubin is> ULN.
Overall, total bilirubin≥ 1.5 x ULN was reported in 76% and 50% of the eltrombopag and placebo groups, respectively.
The results show that mild hepatic impairment total bilirubin> 1 to.
Mean total bilirubin values also remained stable in the baseline to worst post-baseline value analysis.
Hepatic transaminases increased,Weight increased, Total bilirubin increased.
Liver function tests Total bilirubin: 1.5 ULN AST:> ULN can be normal or< ULN if total bilirubin is> ULN.
Systemic safety tests were carried out CBC,creatinine, total bilirubin, AST and ALT.
Increased serum concentrations of total bilirubin and AAG concentrations were associated with a reduced erlotinib clearance.
Regular monitoring of complete blood counts should be conducted in patients with total bilirubin of 1.0-2.0 mg/dl.
For Grade 2 transaminase or total bilirubin elevation, nivolumab or nivolumab in combination with ipilimumab should be withheld.
Abraxane is not recommended in patients that have total bilirubin> 5 x ULN or AST> 10 x ULN.
ALT, AST, and total bilirubin must be monitored in all patients every 2 weeks for the first 3 months of treatment, then as clinically indicated.
There are no data available for patients with severe hepatic impairment total bilirubin> 3 x ULN and any AST.
Echo-guided drainage has shown a technical success of around 90% of cases in addition to a statistically significant improvement in laboratory parameters total bilirubin and GGT.
Alteration of liver function serum albumin<3 g/dL or total bilirubin> 1 mg/dL or prothrombin time> 25% of control;
Ramucirumab has not been studied in patients with severe hepatic impairment total bilirubin> 3.0 ULN and any AST.